An interventional study of Group 1 (Doxorubicin group) and Group 2: Vitamin D group in Melatonin, Breast Cancer Patients Diagnosed and Vitamin D Concentration, sponsored by Tanta University. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Tanta University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing Vitamin D in Breast Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Vitamin D · Breast Neoplasms.
Among the 18 studies testing Vitamin D in Breast Neoplasms, this one is the 7th largest by enrollment, is the only one that started in 2025, is one of 4 with no phase, and was the 18th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →1 of the 18 studies testing Vitamin D in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Abdelrahman Mahmoud · Sites in Egypt
Ages 18–65 · Women only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 1
First in 2005; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 64 across the 18 interventional studies. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 18 has an industry lead sponsor. The 10 most frequent:
Tanta University is the lead sponsor of 1,015 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
14 studies in Breast Neoplasms by Tanta University: 4 open now, 4 under way, 1 of them phase 3. Of 8 finished, 0 (0%) have results posted.
Among the 14 studies in Breast Neoplasms by Tanta University, this one is the 3rd largest by enrollment, is one of 3 that started in 2025, is one of 2 with no phase, and was the 12th registered.
Tanta University’s Breast Neoplasms studies by the year they started, since 2014.
1 of the studies testing Vitamin D in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06596122Abdelrahman MahmoudVitamin D Supplementation in Breast Cancer Patients | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing Vitamin D in Breast Neoplasms, from their registry updates:
Among Tanta University’s 14 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.
Doxorubicin is one of the most potent chemotherapeutic agents and is widely used for the treatment of various cancers and hematological malignancies . Although Doxorubicin has a potential beneficial effect in cancer treatment, its dose-dependent cardio toxicity is considered a major challenge.
Doxorubicin is known to generate free radicals either by redox cycling between a semiquinone form and a quinone form or by forming a Doxorubicin-Fe3+ complex . In both pathways, molecular oxygen is reduced to superoxide ion , which is converted to other forms of reactive oxygen species such as hydrogen peroxide and hydroxyl radical . These free radicals could then cause membrane and macromolecule damage, both of which lead to injury to the heart, an organ that has a relatively low level of antioxidant enzymes such as superoxide dismutase and catalase .
Furthermore, it was revealed that Doxorubicin may enhance the death of cardiomyocytes by affecting the tumor necrosis factor signaling pathway via increasing the expression and levels of inflammatory genes interleukin and interleukin -6 .
To alleviate DOX-induced toxicity, researchers have tested a number of strategies, including the administration of antioxidants and/or antiapoptotic agents, in both in vitro and in vivo models of Doxorubicin induced cytotoxicity, but most of these trials have failed to translate into clinical benefits . As a result, there are no effective approaches for alleviating Doxorubicin induced cytotoxicity despite intensive research over recent decades .
Melatonin is a natural hormone that is primarily secreted by the pineal gland and functions as a major regulator of circadian rhythms in humans . Melatonin also plays a variety of biological roles as a modulator of mood, sexual behavior and sleep; low levels or a deficiency of melatonin are also associated with Parkinson's disease, Alzheimer's disease, epilepsy, ischemic injury, diabetes, and even cancer .
Melatonin has emerged as a promising adjuvant that protects against doxorubicin-induced cytotoxicity, as highlighted by various studies and clinical trials that have demonstrated cardioprotective effects against several chemotherapeutic agents . Moreover, melatonin exhibits low toxicity and easily enters cells owing to its good solubility in both aqueous and organic phases and its highly lipophilic properties . Vitamin D plays an important role in the regulation of body function including the cardiovascular system .
Vitamin D deficiency results in the decrease of active calcitriol leading to inhibition of proliferation of cardiomyocytes and vascular smooth muscles .
This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
30 patients will receive a traditional chemotherapeutic agent (Doxorubicin group) for 12 weeks.
Drug: Group 1 (Doxorubicin group)
patients with Vitamin D supplementation (1000 iu/day) plus Doxorubicin for 12 weeks
Drug: Group 2: Vitamin D group
30 patients with 10 mg of melatonin orally, once daily plus Doxorubicin for 12 weeks.
Drug: Group 3: melatonin group
30 patients will receive a traditional chemotherapeutic agent (Doxorubicin group) for 12 weeks.
patients with Vitamin D supplementation (1000 iu/day) plus traditional therapy for 12 weeks
patients with 10 mg of melatonin orally, once daily plus traditional therapy for 12 weeks
Decreasing incidence and severity of cardiotoxicity
Assessment of decreasing incidence and severity of cardiotoxicity by echocardiogram and ejection fraction is associated with doxorubicin treatment.
Time frame: 12 weeks
Change in Plasma B-Type Natriuretic Peptide (BNP) Concentration
Change in plasma B-type natriuretic peptide (BNP) concentration from baseline to 12 weeks, measured using a chemiluminescent microparticle immunoassay (CMIA) on the Abbott Alinity i analyzer. Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in pg/mL.
Time frame: Baseline and 12 weeks.
Change in N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Concentration
Change in serum/plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline to 12 weeks, measured using a chemiluminescent microparticle immunoassay (CMIA) on the Abbott Alinity i analyzer. Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in pg/mL.
Time frame: Baseline and 12 weeks.
Change in High-Sensitivity Cardiac Troponin I (hs-cTnI) Concentration
Change in serum/plasma high-sensitivity cardiac troponin I (hs-cTnI) concentration from baseline to 12 weeks, measured using the Alinity i STAT High Sensitive Troponin-I chemiluminescent microparticle immunoassay (CMIA). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/L.
Time frame: Baseline and 12 weeks.
Change in Myeloperoxidase (MPO) Concentration
Change in myeloperoxidase (MPO) concentration from baseline to 12 weeks, measured using a human MPO double-antibody sandwich enzyme-linked immunosorbent assay (ELISA; SunRed Biological Technology Co., Ltd.). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/mL.
Time frame: Baseline and 12 weeks.
Change in Interleukin-6 (IL-6) Concentration
Change in interleukin-6 (IL-6) concentration from baseline to 12 weeks, measured using a human IL-6 double-antibody sandwich enzyme-linked immunosorbent assay (ELISA; SunRed Biological Technology Co., Ltd.). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/L.
Time frame: Baseline and 12 weeks.
Change in Creatine Kinase-MB (CK-MB) Concentration
Change in serum/plasma creatine kinase-MB (CK-MB) concentration from baseline to 12 weeks, measured using the Alinity i STAT CK-MB chemiluminescent microparticle immunoassay (CMIA). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/mL.
Time frame: Baseline and 12 weeks.
Plan to share: Yes — All data will be available when needed
Supporting information: Study protocol, Informed consent form
No publications or documents are linked to this record.
Ran from Apr 2025 to primary completion in May 2026, 13 months.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 13 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Apr 2026 → Apr 2025, primary completion Aug 2026 → May 2026 and completion Aug 2026 → May 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vitamin D · Melatonin